Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
November 30, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in...
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
November 28, 2023 08:06 ET
|
Sol-Gel Technologies Ltd.
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial ...
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains...
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023 08:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients...
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will...
Sol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in Canada
June 06, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to...
Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 12, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610...
Sol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an...